

Norberto Guelbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9029366/publications.pdf>

Version: 2024-02-01

13
papers

429
citations

933447

10
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

515
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet Journal of Rare Diseases, 2021, 16, 185.	2.7	17
2	Management of CLN1 Disease: International Clinical Consensus. Pediatric Neurology, 2021, 120, 38-51.	2.1	10
3	Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. Journal of Paediatrics and Child Health, 2021, 57, 519-525.	0.8	15
4	Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Molecular Genetics and Metabolism, 2018, 123, 127-134.	1.1	25
5	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	2.1	80
6	Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. Journal of Inherited Metabolic Disease, 2016, 39, 839-847.	3.6	24
7	Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Molecular Genetics and Metabolism, 2016, 119, 131-143.	1.1	47
8	Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Molecular Genetics and Metabolism, 2015, 114, 186-194.	1.1	33
9	The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2301-2311.	3.8	19
10	Neuronal ceroid lipofuscinosis type CLN2: A new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene, 2013, 516, 114-121.	2.2	40
11	The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Molecular Genetics and Metabolism, 2013, 109, 54-61.	1.1	117
12	Position of Experts Regarding Follow-Up of Patients with Neuronal Ceroid Lipofuscinosis-2 Disease in Latin America. Journal of Inborn Errors of Metabolism and Screening, 0, 8, .	0.3	2
13	Neuronal Ceroid Lipofuscinosis Type 2: A Case Series from Argentina. Journal of Inborn Errors of Metabolism and Screening, 0, 10, .	0.3	0